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Abstract
Cystic fibrosis (CF) is both the most common and most lethal genetic disease in the
Caucasian population. CF is caused by mutations in the cystic fibrosis transmembrane
conductance regulator (CFTR) gene and is characterized by the accumulation of thick,
adherent mucus plaques in multiple organs, of which the lungs, gastrointestinal tract
and pancreatic ducts are the most commonly affected. A similar pathogenesis cascade
is observed in all of these organs: loss of CFTR function leads to altered ion transport,
consisting of decreased chloride and bicarbonate secretion via the CFTR channel and
increased sodium absorption via epithelial sodium channel upregulation. Mucosa
exposed to changes in ionic concentrations sustain severe pathophysiological
consequences. Altered mucus biophysical properties and weakened innate defense
mechanisms ensue, furthering the progression of the disease. Mucins, the high‐
molecular‐weight glycoproteins responsible for the viscoelastic properties of the
mucus, play a key role in the disease but the actual mechanism of mucus accumulation
is still undetermined. Multiple hypotheses regarding the impact of CFTR malfunction
on mucus have been proposed and are reviewed here. (a) Dehydration increases
mucin monomer entanglement, (b) defective Ca2+ chelation compromises mucin
expansion, (c) ionic changes alter mucin interactions, and (d) reactive oxygen species
increase mucin crosslinking. Although one biochemical change may dominate, it is
likely that all of these mechanisms play some role in the progression of CF disease.
This article discusses recent findings on the initial cause(s) of aberrant mucus
properties in CF and examines therapeutic approaches aimed at correcting mucus
properties.
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1 | INTRODUCTION
Cystic fibrosis (CF) is a multiorgan disease with symptoms affecting
tissues that express cystic fibrosis transmembrane conductance
regulator (CFTR) and produce mucus, among those, the lungs and the
gastrointestinal (GI) tract.1-3 Mucus accumulation in the airways,
the intestine, and the pancreatic ducts play a critical role in the
disease pathogenesis by compromising airflow and nutrient digestion.
Since the resulting progressive lung disease can lead to respiratory
failure and ultimately death, this review focuses on studies
conducted on airway mucus, more specifically on secreted mucins
lining the respiratory tree. Mucins are complex macromolecules that
govern the biophysical properties of mucus. In the lungs, gel‐forming
mucins are secreted by goblet cells distributed throughout the
conducting airways and submucosal glands located in the large
airways.4,5 Airway goblet cells secrete MUC5B and MUC5AC to
produce a thin mucus layer that lines the epithelial surfaces. In
contrast, submucosal glands secrete only MUC5B, which is expulsed
from the gland ducts in the form of strands intended to sweep the
large airways and remove inhaled pathogens.6,7 Although both
airway surfaces and glands produce mucus, the biophysical and
biochemical properties of mucus produced by these two compart-
ments may be affected differently by CFTR malfunction and
therefore may play distinct roles in the progression of the CF lung
disease.7 In CF animal models that possess submucosal glands (eg,
pigs and rats), gland hypotrophy and plugging occur at different ages
(ie, newborn vs 6 months) and therefore lung/gland maturation may
play a critical role in the progression of the CF lung disease.8,9 Since
the specific role of gland mucus strands in disease is still being
elucidated, this review will focus on current knowledge of the impact
of CFTR malfunction on the ambulatory mucus layer progressing on
top of the cilia.8,10
The viscoelastic properties of the mucin gel lining the airways are
critical for proper trapping and clearance of pathogens. Gel properties
rely heavily on cys‐rich regions scattered throughout the mucin protein
backbone to organize a complex disulfide‐stabilized polymeric net-
work.11 Adding to the complexity, the physicochemical properties of
mucins are furthermore governed by the large O‐linked oligosaccharide
chains decorating the apomucin core, which can contribute up to 80% of
the mucin molecular mass.12 The O‐glycans are designed to ensure high
volume occupancy in solution, as well as a high water‐holding capacity
for mucin gels and, is important for regulating mucin‐mucin, mucin‐
pathogen, and mucin‐mucosal surface interactions.13 Although, mucins
are produced to protect the mucosa against pathogens, dysregulation of
mucin secretion rate, concentration, expansion, and/or interactions can
compromise the protective role of the mucus layer. In this review, we
discuss how CFTR malfunction can affect mucin biochemical interac-
tions and alter the viscoelastic properties of mucus. Mucins and mucin
gel formation are briefly described herein, followed by an in‐depth
examination of the impact of CFTR on mucin concentration, polymer
compaction, mucin‐mucin interactions, and the impact of oxidative
stress on the mucin network. We conclude by opening the discussion on
current and novel pharmacological approaches aimed at altering the
mucin network (ie, mucoactive agents).
2 | MUCUS AND MUCINS
Healthy airway mucus is composed of approximately 90% to 95% water,
1% to 5% mucins and other proteins, 1% to 2% lipids, and 1% salt
electrolytes.12 Although, hundreds of proteins have been discovered in
airway mucus, mucin proteins primarily govern the viscoelastic gel
properties of the mucus layer.11,12,14 Mucins are large (up to 50MDa) and
heavily glycosylated but the polymeric organization and intracellular
packaging are tightly regulated to ensure the rapid release of high‐quality
viscoelastic gels.12,15 Understanding the structure and organization of a
polymeric mucin gel are critical to investigating how CFTR malfunction
can affect its biochemical and biophysical properties.
2.1 | Mucin structure
Mucins are encoded by MUC genes, a gene family consisting of 18
different proteins.16 Mucins can be divided into two groups: the
secreted (or gel‐forming) and the tethered (or membrane‐bound)
mucins. MUC5B and MUC5AC are the major gel‐forming mucins
expressed in the airways and are predicted to possess different
airway clearance functionalities.6,7 In the GI tract, MUC2 is the
primary gel‐forming mucin expressed that, along with lesser amounts
of MUC6, protects the epithelium from acidic pH, lubricates the
intestine to facilitate transit, and shields the mucosa to prevent
pathogen invasion.17 All gel‐forming mucins share a similar core
protein, referred to as the apomucin. The protein core features von
Willebrand factor (vWF) domains in the N‐ and C‐terminal regions,
cysteine‐rich domains scattered throughout the protein backbone
including the cysteine knot (CK) at the C‐terminal end and a variable
number of tandem repeat (VNTR) region that undergoes extensive
glycosylation and constitutes the bulk of the protein mass (Figure 1).
An important process for the biophysical properties of mucin gels is
the polymeric organization of the mucus, a process dependent on the
capacity of mucin monomers to form dimers and multimers via
C‐ and N‐terminus disulfide bond formation, respectively.11 CK domains
in the C‐terminus are responsible for monomer dimerization, while vWF
domains in the N‐terminus are responsible for the formation of linear
polymers and/or more complex multimeric networks.11,15 In CF,
extracellular DNA originating from dying inflammatory cells entrapped
in mucus can be present in high concentrations and add to the complexity
and entanglement of the polymeric mucin network, increasing gel
viscosity and worsening symptoms of the disease.18
During mucin protein maturation, O‐glycosylation of serine and
threonine residues distributed through the VNTR occurs in the
endoplasmic reticulum. This is a critical step in establishing the biological
properties of mucins, as oligosaccharide composition and terminal sugar
negative charges contribute to mucus swelling via electrostatic interac-
tions and pathogen trapping via specific binding.13,19,20 Glycosylation is
initiated by the linkage of N‐acetyl‐D‐galactosamine, one of three steps
for mucin glycosylation that can yield eight different core structures.
Following the glycan core addition, a backbone structure is linked
followed by the addition of a peripheral terminal sugar, which is the
source for mucin glycan variation. The number of glycans per amino
acid, their distribution pattern, and their size vary from mucin to mucin,
giving each mucin a unique glycosylation profile and therefore specific
biological properties.13
Recent work has shown that mucin proteins interact with
hundreds of other proteins present in the mucus layer, thus further
affecting mucus viscoelasticity and giving rise to the term “the mucus
interactome” to describe the relationship between globular proteins
and mucins.21
2.2 | Mucin sources
In the lungs, gel‐forming mucins are secreted by surface goblet
cells and submucosal glands. Unlike goblet cells that produce
both MUC5AC and MUC5B, submucosal glands only secrete
MUC5B.4,7 These two mucin sources may play different roles in
health and disease, but additional work is needed to determine
their individual functions in the lungs. Mucins at the surface
epithelium are secreted constitutively at basal levels to facilitate
airway maintenance but can also be acutely stimulated for
extensive degranulation following exposure to a challenge like
smoke, allergens, or pathogens.22,23 Complex cholinergic and
purinergic signaling pathways control the rate of mucin granule
release from the glands and the epithelial surfaces, respectively.
In addition, morphological variation has been noted between
mucus released from submucosal glands and goblet cells.6,7
Under cholinergic stimulation, MUC5B is slowly released from
submucosal glands and forms “strands or bundles” with diameters
of 5 to 50 µm. These strands are then “coated” with thin MUC5AC
sheets following their release from goblet cells, resulting in a
MUC5B core‐bundle enveloped by an outer layer of MUC5AC.6,7
It has been postulated that these unique structures are tailored
for mucociliary transport of large (>300 µm) inhaled particles.10
In contrast, surface goblet cells possess heterogeneous popula-
tions of MUC5AC‐rich and MUC5B‐rich granules within the
same cell, and granule release can be regulated by different
exocytotic pathways (ie, basal vs stimulated), suggesting that a
mucin secretion is a delicate event that requires accuracy and
precision.22
Several signaling pathways can initiate mucin granule exocytosis, such
as epidermal growth factor receptor, toll‐like‐receptors, and cholinergic
(Ach) and purinergic (P2Y2) stimulation.
23 Mucin production can be
signaled by an extracellular‐regulated kinase and activation of nuclear
factor‐kappa B.23 Cytokines like interleukin 13 (IL‐13) and IL‐1 are also
important regulators of mucin hypersecretion and influence goblet cell
hyperplasia.24,25 If airway challenges persist, goblet cell hyperplasia,
metaplasia, and gland hypertrophy can ensue, substantially increasing the
amount of airway mucus produced. These phenotypes are commonly
observed in muco‐obstructive diseases such as chronic bronchitis, chronic
obstructive pulmonary disease (COPD), asthma, and CF.26
F IGURE 1 Mucin domains govern
polymeric network organization. Mucin
structure and assembly rely on von
Willebrand factor (vWF) D and C domains in
the N‐ and C‐terminal regions and cysteine‐
rich domains (CysD) scattered throughout the
protein backbone including the cysteine knot
(CK) at the C‐terminal end. The protein core,
which is rich in serine and threonine residues,
undergoes posttranslational O‐glycosylation
(O‐glycans) to form mature mucin monomers.
Dimer formation ensues in the endoplasmic
reticulum and is mediated by disulfide linkage
of the CK domains to form linear, interwoven
polymeric networks
2.3 | Mucin network organization and interactions
The structure and function of mucin gels lend itself to a diverse array
of potential interactions. Although mucus consists of up to 95%
water, its viscoelastic gel properties are the result of disulfide bonds,
hydration capacity, and noncovalent interactions. The intracellular
environment and extracellular milieu dictate how mucin packing,
expansion, and interaction transpire. Recent investigations into
the intracellular arrangement and post‐secretory expansion have
provided key insights into how disease states can alter mucin
interactions.
Mucin exocytosis from goblet cells is extremely rapid and can
take only tens of milliseconds to occur once initiated.20 Before
exocytosis, these large biopolymers, which can reach up to 109 Da,
are tightly packed inside granules ranging in size from 0.5 to 2 µm,
and, for this reason, mucin storage requires a high level of
organization for both packaging and subsequent expansion.15,27
The packing of linear MUC5B polymers is governed by high Ca2+
concentration and acidic pH inside the mucin granules. The presence
of calcium and hydrogen ions inside the granules shields the
negatively charged glycans decorating the apomucins and prevents
electrostatic repulsion, allowing the mucin polymers to organize into
nematic arrangements.15,20 The resulting compacted MUC5B pos-
sesses a central N‐terminus core and outward‐facing C‐termini,
allowing for the formation of linear strands upon release, a feature
advocated to be essential to its putative function of cleaning large
inhaled particles.10 The intracellular organization of MUC5AC is
similar, with C‐terminal dimerization occurring via disulfide bonds in
the ER followed by covalent linkage of the N‐termini in the Golgi and
analogous packing.28
Upon exocytosis, mucin macromolecules undergo dramatic
volume expansion (up to 4000‐fold), a rapid and critical process
that relies on Ca2+ chelation and osmotic pressure.20 To ensure a
fast swelling rate upon exocytosis, organized folding, and unfolding
of the mucins is required to avoid extreme frictional heat
generation.20 The extracellular environment is more alkaline,
higher in bicarbonate and sodium ion concentration, and lower in
calcium ion concentration. Upon opening of the granule in the
extracellular milieu, hydrogen bonds that stabilized the mucins
intracellularly are broken due to increased pH. Simultaneously,
calcium ions are chelated by bicarbonate and exchanged for
sodium ions, promoting additional relaxation of the mucin net-
work.20,29 These ionic changes lead to a large internal osmotic
gradient and subsequent influx of water. Swelling stops once an
equilibrium between osmotic pressure and the intrinsic elastic
component of the matrix is reached.
Once secreted and expanded, mucins are subject to a variety of
intermolecular interactions. Acidic side chains and negatively
charged polysaccharides contribute to the intermolecular formation
of stabilizing salt bridges and electrostatic interactions.30,31 Adding
to the complexity, as the CF disease progresses mucus biophysical
properties are altered by reactive oxygen species (ROS) and/or
airway inflammation.32
To summarize, the noncovalent and covalent interactions,
coupled with the concentration‐dependent interpenetration of the
mucin polymers, help shape the rheological landscape for mucin
gel networks. In the next section, we will discuss how CFTR
dysfunction and restoration of function can impact the mucin
network with regard to physical, biochemical, and biological
interactions.
3 | MUCUS AND MUCIN INTERACTIONS
AT THE CF AIRWAY SURFACE
Static mucus, as observed on CF airway surfaces, is an ideal
environment for bacterial colonization as well as inflammation with
the recruitment of neutrophils that results in irreversible lung
damage.33 Understanding the biochemical processes that occur once
mucins are secreted into the airway surface liquid (ASL) layer and how
they relate to the impairment of mucociliary clearance is crucial to
developing effective treatments for patients with CF. Several hypoth-
eses have been proposed to explain how CFTR malfunction affects the
mucin polymeric network (see Figure 2). Aberrant CFTR‐mediated Cl−
and secretion and dysregulation of epithelial sodium channel (ENaC)‐
mediated Na+ transport results in ASL water hyperabsorption and
subsequent dehydration of the mucus layer. Hyperconcentrated mucins
in the ASL are subject to increased polymeric entanglement with new/
increased solute‐mucin interactions resulting from a concentration
increase of non‐salt molecules in the ASL. In parallel, failure of CFTR to
transport bicarbonate can lead to acidification of the ASL and changes
in the ionic interactions within the mucus layer. Oxidative stress and
inflammation can result in atypical covalent mucin interactions and
potentially change the viscoelastic properties of the gel. All of these
physicochemical changes occur at the airway surface and can alter the
viscoelastic properties of the mucus.
3.1 | Hyperconcentration and mucus gels
Dysfunctional CFTR regulation of ENaC‐mediated Na+ transport is
accepted as the driving force behind the decreased ASL volume in CF
airways, which ultimately increases the osmotic pressure of the
mucus layer and collapses the cilia.34,35 In addition to altered ion and
fluid transport, the CF airways are characterized by goblet cell and
glandular hyperplasia and subsequent overproduction of MUC5B and
MUC5AC.26 As a result, higher mucus concentrations have been
reported in both CF patients and CF model systems.9,36-38 Coupled
together, mucus hypersecretion and airway dehydration produce an
ASL with percent solids reaching five times that of normal levels.37,38
From a polymer physics point of view, two critical concentration‐
dependent transition points contribute to the biophysical behavior of
mucins in the ASL: the semi‐dilute overlap concentration (c*) and the
entanglement concentration (ce).34 The transition from uninteracting
oligomers to an unentangled regime, characterized by mucin chain
overlap, is reported to occur at roughly c* = 1mg/mL for MUC5AC and
MUC2.30,39 These mucins transition from the unentangled overlapping
regime to an entangled regime characterized by mucin chain
interpenetration and reptation at ce of 25 and 30mg/mL for MUC5AC
and MUC2, respectively.39 The incident regimes under normal mucin
concentration and pH values physiologically relevant to the lungs (ie,
~2% solids and 7.0 < pH< 7.2) reflect a semi‐dilute overlapping
network, whereas the gastric mucus is normally an entangled gel in
the normal mucin concentrations and low pH values of the stomach
(pH <2).38 MUC5AC viscosity scales with concentration and behaves
as a purely viscous fluid at concentrations under 25mg/mL (~3% solids
including airway salts). Above 25mg/mL (~3.5% solids), MUC5AC
solutions become viscoelastic, exhibiting both viscous and elastic
behavior. Because CF mucus regularly reaches concentrations above
5% solids, it falls into the latter category, that is, dominated by elastic
gel‐like behavior.34,37
The relationship between physiologically relevant mucin concen-
trations and rheological properties was recently examined and
revealed that airway mucus complex viscosity scales with concentra-
tion.38 Furthermore, macro and microrheology performed on
bovine submaxillary mucus, porcine gastric mucus, and CF and
non‐CF human bronchial epithelial (HBE) cell‐culture mucus over a
range of concentrations showed consistency across mucus types.38
Geometric scaling was consistent between concentration and
complex viscosity, and this held true over the pH range of 6 to 8.
This relationship to concentration also correlated to changes in
mucociliary transport (MCT) and ASL osmotic properties. Hydration
therapy (returning to ~2% solids) profoundly corrected CF sputum
samples to near‐normal viscoelasticity, reinforcing the clinical
findings that administration of hydrating agents such as hypertonic
saline (HS) yields beneficial results in patients with CF40-42 (see
Section 4.1).
A secondary consequence of increased mucin concentration in CF
airways is that the increased proximity of mucin polymers results in
new/stronger interactions with other protein and ionic solutes that
can also affect the viscoelasticity of the gel.31 Indeed, while
physiological mucus behavior is largely governed by the amount of
available solvent, mucin chain dynamics in solution are also
dependent on the number of noncovalent interactions (ie, steric
hindrance from charged residues and/or glycans, as well as
intermolecular salt bridges). Addition of salt to MUC5AC networks
can increase the viscosity of the gel. This has been attributed to
stronger intermolecular interactions taking place as a result of
reduced electrostatic repulsion of the polysaccharide side chains in
the presence of salt31 (this is discussed in greater detail in Section
3.3). Chaotropic agents such as guanidine HCl and urea also reduce
mucus viscoelasticity.30 This is due to the disruption of hydrophobic
interactions and the subsequent unfolding of the mucin protein
backbone. Accordingly, the next sections discuss the relevant mucin‐
solute interactions that contribute to airway mucus physiology and
CF pathophysiology.
F IGURE 2 Model of normal vs CF
airway mucus layer illustrating changes
within the mucus network (ie, polymer
entanglement, mucin compaction, and/or
changes in molecular interactions) in
response to altered ionic fluxes. In normal
individuals, CFTR function ensures proper
Cl− and −HCO3 secretion as well as
regulates Na+ absorption via the
downregulation of the ENaC channel,
controlling water flux through the
epithelium. A thin mucus layer is produced
by airway goblet cells with optimal
biophysical properties (eg, loose
transportable) for airway clearance. In CF,
reduced Cl− and −HCO3 secretion and
increased Na+ absorption can alter the
biochemical interface of the mucin
network in different ways. Mucus layer
hyperconcentration causes a decrease in
mucus mesh size (eg, entanglement).
Impaired Ca2+ sequestering prevents
mucin expansion (eg, compaction). Changes
in hydration, pH, and oxidative stress can
introduce additional ionic, hydrogen,
hydrophobic, and disulfide bonds (eg,
interactions). CF, cystic fibrosis; CFTR,
cystic fibrosis transmembrane
conductance regulator; ENaC, epithelial
sodium channel
3.2 | Ca2+ chelation and mucus compaction
While predominantly a Cl− channel, CFTR also plays a general
anion channel role, and therefore, mutations within CFTR can
further influence the biophysical properties of mucus beyond
dehydration.43 In particular, much attention has been given to the
channel permeability to −HCO3 , both in terms of pH and polycation
chelation.
Inside mucin granules, the environment is rich in Ca2+ ions and
low in pH. Mucin chains are condensed in the granule as nematic
arrays via counterion shielding.15,20 The negatively charged glycans
that would normally repel each other are shielded by Ca2+ ions. A
single Ca2+ ion can neutralize two negative charges, supporting the
formation of a compact intragranular mucin matrix with adjacent
terminal glycans. It has also been proposed that the vWD domains in
the N‐terminus selectively bind calcium during granule packing.15
Upon exocytosis, Ca2+ ions are exchanged for two Na+ ions, as Na+
concentration predominates by over an order of magnitude in the
ASL.20,26 This local increase in internal cation concentrations due to
Na+ influx draws in water and causes swelling of the matrix via a
Donnan effect. Simultaneously, bicarbonate, also abundant in healthy
ASL, chelates the Ca2+ ions that were exchanged for Na+, effectively
sequestering the Ca2+ from reforming an ionic crosslink between
charged mucin glycans.
Improper calcium chelation has been noted as a possible
cause for CF pathogenesis.3 Irregular expansion of secreted
mucins is seen in CF models and can be attributed to ionic
imbalances, particularly related to the lack of bicarbonate and
chloride transport through CFTR.29,44,45 Incompletely unfolded
MUC5B was detected in CF saliva, suggesting that terminal
unpacking of secreted mucins occurs on longer timescales than
previously thought.46 Persistent deficiency of key counterions in
CF likely contributes to keeping the secreted mucins in a semi‐
expanded state causing mucus stasis and plugging, though
hyperconcentration in the ASL was shown to be the predominate
cause of incomplete mucin maturation.46
Counterion donation during unpacking also affects MCT rates.
Addition of zwitterionic HEPES buffer had no effect on MCT,
whereas Tris buffer or addition of bicarbonate increased MCT in CF
rats, and bicarbonate addition to ileum sections of CF mice
normalized mucus properties.9,45 Hence, identifying the counterions
involved in the mucin unfolding and subsequent viscoelastic proper-
ties of secreted mucins is critical. Addition of calcium to pig tracheas
increased ASL viscosity, but other divalent ions like magnesium and
zinc had no rheological effect.47 This distinction is important when
considering the development of chelating compounds as therapies
for CF. Although calcium chelation during mucin exocytosis may be
crucial to the unfolding of the mucin, a continuous low‐calcium
environment is necessary to promote normal rheological proper-
ties.47 If altered ionic fluxes persist after secretion, normally unfolded
mucins can begin to interact in an aberrant manner, possibly causing
increases in ASL viscosity.
3.3 | Acidic pH and mucus gels
The role of CFTR in bicarbonate transport and subsequent acidifica-
tion in CF airways and models have been known for years.48 Mucus
pH in CF nasal airways has been measured as low as approximately
6.5, and in vitro models of CF have shown greater susceptibility to
pH changes than controls.49,50 Even small changes in hydrogen ion
concentration may have important consequences given how resi-
liently the body regulates pH and have been implicated in the
increased susceptibility of patients with CF to infection.51
Recent work showed an inverse correlation between the pH and
viscosity of MUC5AC gels.30,31 MUC5AC begins to act more like a
solid at low pH levels (pH <4), shown rheologically by a decrease in
tan (δ), the ratio of the loss modulus (G′′) to the storage modulus (G′).
The storage modulus increases with decreasing pH, indicating that
the mucus becomes more gel‐like, evidence of additional crosslinking
and/or increased mucin interaction in the gel‐phase. Biochemically,
this can be explained by protonation of the carboxyl side chains of
residues such as glutamic and aspartic acid, leading to disruption of
intramolecular salt bridges and causing the mucin to unfold. The
unfolding of the mucin exposes hydrophobic sites hidden in the
native conformation of the protein. The newly exposed hydrophobic
domains govern the interaction of the now‐neutrally charged mucin
molecules, reducing the elasticity and increasing the viscosity of the
MUC5AC gel. This is in agreement with additional studies on
microrheology of gastrointestinal mucins (MUC2) at low pH levels.30
Salt bridge protonation and hydrophobic interactions are likely the
driving forces behind the sol‐gel transition of mucins below pH 2.
These pH ranges are physiologically relevant to the stomach and
portions of the GI tract but not to human airways. Therefore, a few
important distinctions must be made when comparing data from
recent publications. While the protonation of carboxyl side chains in
the protein backbone is a probable mechanism for increasing
intermolecular interactions and gel viscosity, it is crucial to note
that the pKa’s of glutamatic and aspartic acid are 4.15 and 3.71,
respectively. At pH values of approximately 2, such as in the stomach,
these side chains are approximately 99% protonated. However, with
hydrogen ion concentrations 104 to 106 lower (ie, pH 6.5), such as in
the lungs, the carboxyl side chains of the acidic amino acids remain
deprotonated. Examination of porcine ASL viscosity in the pH range
of approximately 6.5 to 8.0, much more physiologically relevant to
human airways, revealed that ASL viscosity at the small length‐scales
probed by fluorescence recovery after photobleaching assays
increased slightly under acidified conditions.47 However, because
increased ASL viscosity as a function of acidity did not correlate with
disulfide bond formation nor bicarbonate concentration, it is likely
due to altered electrostatic interactions between mucin molecules.
Although viscosity changes were modest (eg, 4‐6‐fold) compared
with the several‐log fold changes with respect to concentration
reported in GI and airway mucus studies, small changes in pH can
have critical physiological consequences and contribute to CF
pathogenesis by altering MCT.30,38
3.4 | ROS and mucus crosslinking
Evidence of increased levels of ROS in patients with CF has been
documented for decades and is thought to play a role in the
progression of CF pulmonary dysfunction.52 Inflammatory immune
cells, notably polymorphonuclear (PMN) neutrophils, produce
oxidants (such as superoxide anion, hydrogen peroxide, and hypo-
chlorous acid) when defending against infection.52 Myeloperoxidase
(MPO), a pro‐oxidant enzyme secreted by PMN neutrophils, is
present in the ASL of patients with CF and methionine sulfoxide, a
byproduct of MPO oxidation, has been correlated with early CF lung
disease and bronchiectasis.52,53 This is of particular interest because
recent findings showed that neutrophil‐dominated inflammation
occurs in the absence of infection.36,54 In addition, lower concentra-
tions of the antioxidant glutathione were measured in CF bronch-
oalveolar lavage fluids, furthering the potential for oxidative
damage.55
Limited data exist on the effects of ROS on mucins. While
cysteine residue distribution for the same mucus concentration was
similar between CF and non‐CF controls, disulfide bond concentra-
tion was higher in the CF population and correlated with ROS
levels.32 Furthermore, simulated crosslinking of healthy mucus
samples with dimethyl sulfoxide or oxygen (O2 gas mimicking
treatment for hypoxia) increased the elastic modulus of the
solution.32 Disulfide bond formation is a crucial step to proper mucin
synthesis and function; however, excessive disulfide bridging may
play a role in the pathophysiology of muco‐obstructive diseases. The
likely explanation is that high levels of MPO induce posttranslational
oxidative modifications of cysteine residues. In CF and asthma,
inflammatory enzymes released by neutrophils and eosinophils,
respectively, initiate the oxidation of free thiols/cysteine to form
additional disulfide bridges or cysteine.32,56 The reaction is specu-
lated to involve MPO or eosinophil peroxidase entrapped in mucus
that catalyzes the reaction of H2O2 with thiocyanate to generate
potent local oxidants. The subsequent increase in mucin disulfide
interactions causes polymer network crosslinking and stiffening of
the mucus gel. The viscoelastic changes resulting from mucus
oxidization were of a similar magnitude to that of fivefold
concentration changes. These bonds are potential therapeutic targets
and can be broken by reducing agents such as NAC, dithiothreitol
(DTT), and tris(2‐carboxyethyl)phosphine (TCEP) (see Section 4.5).
4 | PHARMACOLOGICAL APPROACHES
TARGETING MUCUS
Improvement of mucus clearance in CF is key to preventing declines
in lung function. CFTR‐directed therapies have been shown to
improve mucociliary clearance (MCC) in vivo, with ivacaftor produ-
cing a approximately 10% increase in MCC in patients with a G551D
mutation.57,58 In the age of CFTR‐corrective therapies, patients
with mutations not responsive to modulator compounds (eg,
nonsense mutations) will require symptomatic treatment via
CFTR‐independent approaches. In addition, patients treated with
CFTR modulators may still benefit from therapies improving
clearance as mucus plugging will persist due to residual infections
and permanent lung damage. In recent years, therapeutic strategies
aimed at changing the viscoelastic properties of mucus have gained
momentum. Mucus provides a relevant therapeutic target for all
patients regardless of genotype (unlike CFTR modulators) and/or
inflammatory status (unlike dornase alfa). Compounds that change
the biophysical properties of mucus are commonly called “mucoac-
tive” but do not always work directly on mucins (eg, dornase alfa
breaks down extracellular DNA). As a result of the complexity of
mucus and the intricate interactions of the mucin network, a wide
range of pharmacological approaches, including osmotic agents, ion
channel potentiators and inhibitors, Ca2+ chelators, surfactants, and
reducing agents are currently being tested or have been approved
and are discussed in this section.
4.1 | Osmotic agents
Osmotic agents, compounds that cause water to be drawn into the
airway surfaces, have the potential to treat muco‐obstructive
diseases like CF and COPD by “reversing” the effects of water
hyperabsorption via the ENaC channel. Inhalation of HS is clinically
efficacious although the precise mechanism of action has not been
completely elucidated.40-42 The current hypothesis is that adminis-
tration of HS causes fluid influx into the airway lumen. Once water
flows into the lumen, it hydrates and swells the ASL, with the
magnitude of swelling being governed by mucus concentration (ie,
the higher the mucus concentration, the longer the duration of ASL
swelling).42 Hence, mucus hyperconcentration in CF provides an
additional osmotic driving force, potentially via counterions on the
mucin glycans. Interestingly, ENaC inhibition increased the response
to HS in vitro, indicating that sodium reabsorption likely diminishes
the effect of aerosolized HS, which establishes another therapeutic
target in CF (see Section 4.2).
Supported by a straightforward mechanism of action, many
clinical trials have tested the effect of osmotic agents on lung
function and MCC in patients with obstructive lung disease. HS (7%
NaCl) was first shown to be clinically effective over a decade ago.40,41
Administration of HS was shown to increase lung function (FVC and
FEV1) and decrease pulmonary exacerbations in patients with CF.
41
HS was also shown to increase MCC in a sustained fashion in vivo
and expedited symptom resolution during hospitalization.40,41
Another osmotic agent, mannitol, has also shown clinical
potential to treat obstructive airway diseases and has been approved
in the EU, Australia, Israel, and recently the USA. Mannitol is an inert
sugar that is not absorbed by the GI tract, not metabolized, and does
not cross the blood‐brain barrier. The mechanism of action is
postulated to be similar to HS, exerting its effects by creating an
osmotic gradient and drawing water into the airway lumen. In
contrast to the Na+ in HS, mannitol has no transcellular absorption
pathway. While Na+ is hyperabsorbed in CF, mannitol absorption
rates are unaffected by the ion transport defects in CF, possibly
explaining why it contributes to decreased paracellular small‐
molecule probe absorption rates as measured using gamma scinti-
graphy.59 Inhalation of dry powder mannitol increased FEV1 in
patients with CF and improved MCC in healthy, asthmatic,
bronchiectasis, and CF subjects.60,61 Because mannitol can be
administered as a dry powder, there is no need for nebulization.
This added convenience may reduce treatment time and improve
adherence to treatment plans.
4.2 | Non‐CFTR ion channel agents
In addition to therapies that directly affect the osmolarity of the ASL,
ENaC blockers have the potential to increase ASL hydration by
inhibiting active Na+ absorption via the ENaC channel. While
inhibition of ENaC has been shown to positively affect ASL hydration,
ENaC‐blocking small‐molecule therapies have, in general, been
unsuccessful at producing long‐term benefits in patients with CF.62
Lack of efficacy of these drugs can be attributed to their short half‐
life, while effects on renal ion transport are the key dose‐limiting
safety concern.63,64 Currently, several ENaC modulators are being
tested in clinical trials. Compound AZD5634 from AstraZeneca
recently completed two phase I trials. AZD5634 was well tolerated
both intravenously and inhaled at all dose levels during a phase Ia
pharmacokinetic evaluation, however, data regarding its effect on
MCC has not yet been released from the completed phase Ib trial.65
VX‐371 from Vertex (formerly P‐1037) is under investigation as well,
being tested alone, in combination with HS, or in combination with
Orkambi for patients with CF and has also been tested in patients
with primary ciliary dyskinesia.66
In CF, ENaC upregulation is partly due to the proteolytic degradation
of SPLUNC1, an inhibitory defense protein responsible for cellular
internalization of the ENaC protein.67,68 By this mechanism, SPLUNC1
reduces active sodium absorption via ENaC and, in turn, prevents ASL
dehydration. Neutrophil elastase, present in high concentrations in CF
sputum, degrades SPLUNC1 and, therefore, favors ENaC upregulation
and/or fluid hyperabsorption.69 SPX‐101, an ENaC blocker created by
Spyryx Biosciences, is a peptidomimetic compound that resembles the
active ENaC‐inhibiting region of the SPLUNC1 protein and is not
degraded by proteases found in CF sputum.70 SPX‐101 has been tested
in clinical trials in patients with CF, and non peer‐reviewed data from a
phase II study shows a 5.2% increase in FEV1 in SPX‐101‐treated patients
compared with the placebo control group.71
Another approach is to potentiate other chloride channels
already expressed in the lungs. TMEM16A or anoctamin‐1 is a
voltage‐sensitive calcium‐activated chloride channel (CaCC) ex-
pressed in epithelial tissues such as the gut and the airways. Like
CFTR, TMEM16A has the capacity to regulate Cl− currents directly or
indirectly via the control of CFTR‐mediated Cl− secretion.72 Counter-
intuitively, inhibition of TMEM16A is speculated to promote clinical
benefits, as TMEM16A expression was linked to goblet cell
metaplasia.73,74 In parallel, TMEM16A potentiators are currently
being tested in vitro by Enterprise Therapeutics; the drugs were
reported to positively stimulate anion conductance and fluid
secretion in CF cultures.75 With the same objective of increasing
Cl− secretion, denufosol, a P2Y2‐receptor agonist that stimulates Ca2+
elevation and activates CaCC channels, made its way to clinical trials
in 2008. However, inhalation of denufosol for 48 weeks failed to
improve pulmonary function in patients with CF.76,77 TMEM16A may
provide an alternate route to address muco‐obstructive lung disease
but warrants further investigation. Another anion channel, SLC26A9,
is also being studied as a potential therapeutic target in CF, although
limited data exist at this time.78,79
4.3 | Chelating agents
In CF, the secretion of bicarbonate, an alkalinizing but also a chelating
agent, is diminished.80 As a result, calcium chelation, a critical step
during mucin granule exocytosis may be hindered and mucin maturation
(ie, transition from a compacted to an expanded form) may be
compromised.46 The addition of high concentrations of bicarbonate to
CF airway model systems like the CF rat and pig trachea has been
shown to increase MCT rates and change the proportion of condensed/
expanded mucins.9,46 Conversely, the addition of free calcium ions to pig
tracheal surfaces was found to increase ASL viscosity, supporting that
calcium sequestering is necessary for healthy airway mucus rheology.47
Zinc and magnesium, both also divalent cations, do not change the ASL
viscosity; therefore, chelation therapies specifically targeting calcium
are of particular interest.47
Ethylenediaminetetraacetic acid (EDTA), a hexadentate ligand
capable of chelating metal ions, has been used in CF models to bind
calcium and normalize mucus properties.45 Compared side by side on
mucus from the ileum of CF mice, EDTA‐induced rheological changes
that were similar to bicarbonate at roughly sixfold lower concentra-
tions (20 vs 115mM).29 A similar compound more selective for
calcium chelation, ethylene glycol‐bis(β‐aminoethyl ether)‐N,N,N′,N′‐
tetraacetic acid, has also been used in CF research to provide calcium
chelation at even lower concentrations than EDTA.47 Unfortunately,
tissue integrity was found to be compromised by both 20mM EDTA
and 115mM bicarbonate, suggesting that these compounds are
likely, not suitable for human treatment.29
OligoG, a guluronate‐rich alginate with a high affinity for calcium
ions, facilitated the removal of adherent mouse ileum mucus at
concentrations as low as 1.5%, while showing no effect on tissue
integrity at concentrations as high as 6%.81 It has been speculated
that concentrations of 1.5% can be reached in the lungs via dry
powder inhalation.81 One phase II clinical trial was recently
completed and another trial is currently underway for the treatment
of CF patients with OligoG.82 Preliminary data from a recent phase II
trial showed that although there was not a significant difference in
MCC, a strong trend towards a more peripheral deposition of tracer
particles was observed in subjects treated with OligoG, suggesting
the opening of previously occluded airways.82
Recently, a polycationic biopolymer, poly (acetyl, arginyl) glucosamine
(PAAG) was used in in vitro and in vivo models of CF to displace Ca2+ and
promote optimal expansion and linearization of mucins upon exocyto-
sis.83 The high‐molecular‐weight polyglucosamine significantly improved
the viscoelastic properties of CF sputum and CF HBE mucus. In addition,
PAAG increased the ciliary beat frequency and MCT in CF HBE cultures,
which correlated with the alteration of the MUC5B network ultra-
structure towards a more linear organization. Treatment of CF mice via
oral gavage and CFTR‐KO ferrets via aerosolization resolved intestinal
and airway plugging, respectively. Furthermore, PAAG‐treated ferrets
revealed significantly lower levels of inflammatory markers, suggesting
Ca2+‐chelating agents may be a valid therapeutic approach to treat
patients with CF.
4.4 | Surfactants
Surfactants are surface‐active agents that reduce the surface tension
between a liquid and another substance (eg, liquid, gas, or solid) and
work by interfacing between the hydrophilic and hydrophobic
components of a solution. Relevant to polymer gels, the addition of
surfactants can interact with the hydrophobic regions of the mucin
network as well as the interface of the ASL. The disruption of
hydrophobic interactions thus disperses the mucin‐rich fraction of
the gel, creating a more homogenous or a single‐phase gel with lower
viscosity.31 Adding surfactant to an electrostatically charged system
like a mucin gel initiates the formation of polymer‐surfactant
aggregates and, at a critical concentration, a single‐phase is obtained.
Mucin polymers then no longer interact with each other via
hydrophobic interactions, reducing surface affinity and increasing
water solubility. Hence, adding surfactant increases the homogeneity
of a mucin‐rich solution and decreases hydrophobic crosslinking of
the gel.
Nonionic surfactants such as 1,2‐hexanediol effectively reduce
both the storage and loss moduli of MUC5AC gels and prevent
assembly of mucins via hydrophobic interactions.31 The elastic
modulus decreases with increasing concentrations of surfactant until
a single population is governed by Brownian motion.31
Surfactant interaction with the mucus layer could be relevant as
both a treatment option for muco‐obstructive diseases as well as a
pertinent area of research for drug delivery through mucus gel
systems. For example, combining proteolytic enzymes such as papain‐
palmitate with surfactant compounds in the form of self‐emulsifying
drug delivery systems increased enzyme activity likely due to
improved mucus permeability.84 Clinical data on surfactants is
conflicting, with studies showing positive results in patients with
chronic bronchitis, negative results in healthy patients with rhinosi-
nusitis, and neither benefit nor harm in patients with CF.85-87
4.5 | Reducing agents
Another approach different from hydration therapies is fragmen-
tation of the mucin network itself. Therapies targeted at
chemically breaking down mucus (mucolytics) have been used for
decades. The most common and most effective “mucolytic” used in
CF is inhaled dornase alfa, a recombinant human DNase that works
by enzymatically digesting extracellular DNA released by dying
neutrophils entrapped in mucus.88 Due to its target, dornase alfa
was shown to be most effective in patients with CF presenting
with inflammation and was found to be ineffective in patients with
other obstructive airways diseases (eg, COPD).89,90 Despite
targeting a macromolecule other than mucins, the clinical benefits
of rhDNase confirmed the notion that an inhaled drug affecting
the rheology of airway secretions could improve health outcomes.
However, NAC, a thiol‐based compound that directly affects the
mucin network by cleaving intra‐ and intermolecular disulfide
bonds, showed only limited in vivo efficacy.91,92 Nevertheless,
the concept that reducing mucin disulfide bonds decreases the
viscoelastic properties of mucus has been broadly demonstrated
and can be explained by basic polymer physics. To facilitate
clearance or lubrication, mucins interact by forming loosely
interwoven mucus networks comprised of linear disulfide‐linked
mucin polymers able to reptate.20,30 Reducing disulfide bonding
was shown to lower the viscoelastic properties of the mucus
because network stability is dependent on the second power of the
length of the polymers that form the network.30,93 Breaking mucin
polymers into smaller oligomers, therefore, significantly decrease
the random walk time and allows for greater axial diffusion.30
The concept of a stiffer mucus dominated by disulfide bridges is
of great interest as it unveils a commonly overlooked target for
therapeutic intervention. Diseased mucus may require greater
reducing power than healthy mucus to achieve similar results.
Despite the lack of clinical efficacy, NAC has been the only reducing
agent approved for inhalation since the 1960s.
Our recent study described the limitations of NAC as an inhaled
reducing agent.94 In brief, we showed that NAC possesses a low
intrinsic reducing activity, as it mostly remains in its inactive
protonated form at physiological pH and cycles slowly between
active and inactive forms. As a result, NAC requires long periods of
time to react to completion and the drug is rapidly cleared and/or
absorbed from the epithelial surfaces. Consequently, the limited
potency and slow kinetics of NAC, coupled with the off‐target
irritation effects including cough and bronchospasm, appear respon-
sible for its failure in clinical pulmonary medicine as an inhaled
mucolytic. Identifying the deficiencies of NAC is the first step
towards preclinical testing of the next generation of reducing agents.
Other reducing agents are commonly used in laboratories but
have limited or poor toxicity data. DTT exhibited a faster reaction
time and increased potency compared with NAC. However, due to its
cell toxicity, DTT cannot be used in vivo for the treatment of CF
patients.95 Similarly, TCEP is also used in laboratories and has the
advantage of being odorless, but limited toxicological data exists on
this compound.
TCEP was tested for MCT activity ex vivo and in vivo in newborn
pigs following stimulation of submucosal gland secretion with
methacholine. Mucus clearance rate was assessed by tracking the
velocity of large metal particles (>300 µm) across the airway surface.
Although TCEP did not affect the overall velocity of the particles, it
decreased the percentage of particles in movement, which correlated
with a delay in clearance via the action of mucus strands originating
from submucosal ducts.10 Hence, designing novel reagents will be a
balancing act between increasing potency, improving kinetics, and
preventing off‐target effects and cell toxicity.
Parion Sciences designed several new thiol reagents (eg, P‐
3001, P‐2062, and P‐2119) that were tested in in vitro and in vivo
models. Compared with NAC, P‐3001 showed superior reducing
activities including faster reaction rates.94 P‐3001 required lower
concentrations to alter the viscoelasticity of patient sputa and
reduced mucus burden in βENaC mice, a model of CF lung
disease. Drug effects were achieved without evidence of in vitro
or in vivo toxicity. Similarly, P‐2062 was more effective than NAC
and rhDNase at dissolving mucus flakes collected via bronchoal-
veolar lavages performed on CF preschoolers.36 Mucus flake
integrity is also affected by treatment with TCEP (Figure 3).
Although TCEP treatment of pig trachea delayed the mobilization
of microdisks, P‐2062 treatment accelerated tracheal mucus
velocity in a sheep model of muco‐obstructive lung disease,
suggesting that the overall MCT is not negatively affected.36
MUC5B overexpression has been shown to be a risk factor
for developing idiopathic pulmonary fibrosis (IPF).96 In the bleomy-
cin‐challenged MUC5B‐overexpressing mouse model of IPF, P‐2119
restored MCT and minimized fibrosis following lung injury.97
These studies demonstrated that reducing the viscoelasticity
of airway mucus with reducing agents may be an achievable
therapeutic goal and provides unique insights into new mucolytic
agents as inhaled therapies to treat a broad range of muco‐
obstructive diseases.
5 | CONCLUSION AND FUTURE
DIRECTIONS
Mucus is a complex polymeric gel that serves as a critical defense
mechanism in multiple organ systems. In muco‐obstructive diseases like
CF, restoring proper mucus viscoelasticity and clearance in the lungs
remain major goals. The advancement of CFTR correctors and
modulators provide an exciting glimpse at how CFTR correction can
change the course of CF pathogenesis. However, some patients remain
ineligible for modulator therapies and rely on symptomatic treatments to
control their disease. While knowledge surrounding mucin biochemistry,
ASL interaction, and MCT has expanded rapidly in the past decade, there
is still much to learn. Understanding the precise biochemical and
biophysical mechanisms of both normal and aberrant mucus will help
guide treatment efforts and ensure that all patients suffering from muco‐
obstructive diseases receive effective therapies.
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